# mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)

> **NCT03288350** · PHASE2 · UNKNOWN · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 55 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** mDCF + Avelumab

## Key facts

- **NCT ID:** NCT03288350
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-22
- **Primary completion:** 2020-12
- **Final completion:** 2023-12
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2018-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288350, "mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03288350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*